Active Sur­veil­lance for Thyroid Cancer

What is active sur­veil­lance?

Active surveillance is a planned program of monitoring a known cancer. The care team checks for changes and discusses treatment if it becomes necessary or the patient prefers it. The cancer remains in place during monitoring.

This guide focuses on selected small papillary thyroid cancers. It does not describe follow-up after cancer treatment or routine monitoring of a benign thyroid nodule.

Who may qualify?

The 2025 American Thyroid Association guidelines support considering active surveillance for selected papillary thyroid cancers measuring 1 centimeter or less, without evidence of lymph node or distant spread. Size alone is not enough to decide.

The team assesses tumor location, signs of invasion, biopsy findings, overall health, and ability to attend follow-up. Aggressive cancer features or a location where growth could threaten the windpipe or a voice nerve may make surveillance unsuitable.

What does monitoring involve?

Neck ultrasound examines the cancer and nearby lymph nodes. The ATA describes ultrasound every 6 months for the first 1 to 2 years, then annually. Your clinician sets the schedule; the necessary total duration remains uncertain.

Keep follow-up appointments even when you feel well. Before choosing surveillance, discuss travel, costs, access to experienced ultrasound staff, and how records will transfer if you move. Learn more about thyroid ultrasound.

When might surgery be recommended?

Reasons include tumor growth of at least 3 millimeters, new biopsy-confirmed cancer in lymph nodes, spread outside the thyroid, or growth toward vulnerable structures. Difficulty continuing follow-up, anxiety, or a preference for treatment also warrant a surgical discussion.

You can revisit the decision with your team. Choosing surgery later does not mean that choosing monitoring was a mistake. The thyroid cancer guide explains treatment options more broadly.

What are the benefits and limitations?

Surveillance can delay or avoid an operation and its possible complications. It preserves the thyroid gland, although a person may still need thyroid medicine for another thyroid condition.

The tradeoff is continued monitoring of a known cancer. Some tumors grow or spread, and some patients eventually need treatment. Follow-up involves time, expense, and uncertainty.

In a 2025 Canadian study of 200 patients with small, low-risk papillary thyroid cancer, 155 initially chose surveillance. Over a median follow-up of about 6 years, 37 of those patients had treatment completed or recommended, most often because of progression or patient preference. No thyroid cancer deaths or distant spread were observed in the study. These results came from a specialist center and do not guarantee an individual outcome. Read the study.

How might sur­veil­lance affect daily life?

People respond differently to living with a known cancer. Some feel comfortable with monitoring; others find the uncertainty difficult. Tell your team if worry affects sleep, relationships, or daily activities.

Ask for a written follow-up plan, a contact for questions between visits, and support with making the decision. Your preferences matter throughout care.

Questions to ask your clinician

• What makes my cancer suitable or unsuitable for surveillance?
• Is it near a nerve, the windpipe, or another important structure?
• Who will perform and compare my ultrasounds?
• How often will I need visits, and what will they cost?
• What specific changes would lead you to recommend surgery?
• What happens if I move, miss a visit, or change my mind?
• What are the benefits and risks of surgery for my situation?